Ranbaxy to Appeal Preliminary Injunction Against Sales of Quinapril

Main Category: Pharma Industry / Biotech Industry
Article Date: 03 Apr 2005 - 2:00 PDT

email to a friend   printer friendly   opinions  

Ranbaxy Laboratories Limited (Ranbaxy) announced today that the U.S. District Court for the District of New Jersey hearing the preliminary injunction motion brought by Pfizer against Teva Pharmaceuticals USA, Inc. (Teva) and Ranbaxy Pharmaceuticals Inc. (RPI) enjoined Teva and RPI from selling RPI's quinapril tablets (5, 10, 20, and 40 mg). Pfizer had asserted that RPI's quinapril tablets, which have been marketed through an exclusivity relinquishment arrangement with Teva, were infringing U.S. Patent No. 4,743,450 literally and under the doctrine of equivalents.

Jay Deshmukh, Ranbaxy's Vice President, Intellectual Property, stated, that while Teva and RPI will comply with the preliminary injunction they also will immediately file with the U.S. Court of Appeals for the Federal Circuit an appeal to have the injunction lifted and a motion to expedite the appeal. Jay further stated that RPI is confident that it will, on appeal, be able to make a compelling argument in support of its non-infringement position.

Ranbaxy Pharmaceuticals Inc. ("RPI") based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited ("RLL"), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, manufactures and markets brand and generic pharmaceuticals and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development. The Company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 44 countries and manufacturing operations in 7 countries.

ranbaxy.com/newsroom/pressrelease_det.asp?sno=203

• Additional
• References
• Citations